ArticleJournal of advanced research2023
Human corneal stromal stem cells express anti-fibrotic microRNA-29a and 381-5p - A robust cell selection tool for stem cell therapy of corneal scarring.
Article in Journal of advanced research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 30 citations in OpenAlex.
- M1-primed human corneal stromal stem cell-derived exosomes delivering protein-coding transforming growth factor-β3 RNA promote corneal regeneration.Stem cells translational medicine · 2026Article
- The Role of Epigenetics in Corneal Fibrosis.Epigenomes · 2026Review
- Role of stem cells in ocular diseases: Progress and challenges.Journal of biomedical research · 2026Article
- Morphological characteristics of corneal stromal stem cells and their age-related decline.Scientific reports · 2026Article
- The Therapeutic Potential of Exosomes in Ocular Surface Diseases.Biomolecules · 2026Review
- Human Corneal Stromal Stem Cell Treatment Reduces Established Opacities in Chronic Corneal Scarring.Cells · 2026Article
- Macrophage Extracellular Vesicles: Therapeutic Strategies for Corneal Fibrosis in Rare Diseases.Biomolecules · 2026Review
- Corneal stromal stem cell-derived extracellular vesicles inhibit corneal neovascularization.Indian journal of ophthalmology · 2026Article
- Exosomes in corneal diseases: advances in diagnosis and therapy.Frontiers in cell and developmental biology · 2026Review
- Immune cell dynamics and cytokine regulation in cornea and transplantation.Frontiers in immunology · 2026Review
- Review
- miR29a-Loaded Extracellular Vesicles Derived from Human Mesenchymal Stem Cells Inhibit Fibrotic and Inflammatory Signaling.ACS omega · 2025Article
- Scientometric analysis of extracellular vesicles in vision science (up to 2024).Journal of nanobiotechnology · 2025Review
- Review
- LNP-encapsulated miRNA29b for corneal repair: A novel approach to combat fibrosis.Materials today. Bio · 2025Article
- Developing stem cells for corneal disease: recent developments and future perspectives.Regenerative medicine · 2025Review
- Isolation, Culture, and Quality Assessment of Clinical-Grade Corneal Stromal Stem Cells.Methods in molecular biology (Clifton, N.J.) · 2025Article
- A Full Good Manufacturing Practice-Compliant Protocol for Corneal Stromal Stem Cell Cultivation.Bio-protocol · 2024Article
- Anti-Inflammatory and Anti-(Lymph)angiogenic Properties of an ABCB5+ Limbal Mesenchymal Stem Cell Population.International journal of molecular sciences · 2024Article
- Advances in Extracellular-Vesicles-Based Diagnostic and Therapeutic Approaches for Ocular Diseases.ACS nano · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
introductionCorneal blindness due to scarring is treated with corneal transplantation. However, a global problem is the donor material shortage. Preclinical and clinical studies have shown that cell-based therapy using corneal stromal stem cells (CSSCs) suppresses corneal scarring, potentially mediated by specific microRNAs transported in extracellular vesicles (EVs). However, not every CSSC batch from donors achieves similar anti-scarring effects.
objectivesTo examine miRNA profiles in EVs from human CSSCs showing "healing" versus "non-healing" effects on corneal scarring and to design a tool to select CSSCs with strong healing potency for clinical applications.
methodsSmall RNAs from CSSC-EVs were extracted for Nanostring nCounter Human miRNA v3 assay. MicroRNAs expressed > 20 folds in "healing" EVs (P < 0.05) were subject to enriched gene ontology (GO) term analysis. MiRNA groups with predictive regulation on inflammatory and fibrotic signalling were studied by mimic transfection to (1) mouse macrophages (RAW264.7) for M1 phenotype assay; (2) human corneal keratocytes for cytokine-induced fibrosis, and (3) human CSSCs for corneal scar prevention in vivo. The expression of miR-29a was screened in additional CSSC batches and the anti-scarring effect of cells was validated in mouse corneal wounds.
resultsTwenty-one miRNAs were significantly expressed in "healing" CSSC-EVs and 9 miRNA groups were predicted to associate with inflammatory and fibrotic responses, and tissue regeneration (P <10
conclusionWe characterized the anti-inflammatory and fibrotic roles of miR-29a and 381-5p in CSSCs, contributing to scar prevention. MiR-29a expression in EVs distinguished CSSCs with anti-scarring quality, identifying good quality cells for a scarless corneal healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.